These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 35948602)

  • 1. Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis.
    Uson Junior PLS; Carvalho L; Fernandes MLC; Botrus G; de Souza Martins R; da Silva EF; Dos Santos SSMB; Taniwaki L; Taranto P; Dutra ACP; de Oliveira Filho JB; Araujo SEA; Moura F
    Sci Rep; 2022 Aug; 12(1):13592. PubMed ID: 35948602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
    van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
    Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
    Versteijne E; van Dam JL; Suker M; Janssen QP; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Tienhoven G; van Eijck CHJ;
    J Clin Oncol; 2022 Apr; 40(11):1220-1230. PubMed ID: 35084987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
    van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
    JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
    Barnes CA; Aldakkak M; Christians KK; Clarke CN; Dua K; George B; Ritch PS; Kamgar M; Hall WA; Kulkarni N; Erickson BA; Evans DB; Tsai S
    Surgery; 2020 Sep; 168(3):440-447. PubMed ID: 32641278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
    Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
    Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: a systematic review and network meta-analysis of randomized clinical trials.
    He J; Lv N; Yang Z; Luo Y; Zhong W; Wu C
    Int J Surg; 2024 Jun; 110(6):3900-3909. PubMed ID: 38935819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
    Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
    Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.
    Brown ZJ; Heh V; Labiner HE; Brock GN; Ejaz A; Dillhoff M; Tsung A; Pawlik TM; Cloyd JM
    Br J Surg; 2022 Dec; 110(1):34-42. PubMed ID: 36346716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Zou Y; Gao S; Yu X; Zhou T; Xie Y; Guo X; An R; Wang X; Zhao T; Chang A; Gao C; Yu J; Hao J
    Int J Surg; 2023 Jun; 109(6):1573-1583. PubMed ID: 37132194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer.
    Shrestha B; Sun Y; Faisal F; Kim V; Soares K; Blair A; Herman JM; Narang A; Dholakia AS; Rosati L; Hacker-Prietz A; Chen L; Laheru DA; De Jesus-Acosta A; Le DT; Donehower R; Azad N; Diaz LA; Murphy A; Lee V; Fishman EK; Hruban RH; Liang T; Cameron JL; Makary M; Weiss MJ; Ahuja N; He J; Wolfgang CL; Huang CY; Zheng L
    Cancer Med; 2017 Jul; 6(7):1552-1562. PubMed ID: 28639410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre.
    Roselló S; Pizzo C; Huerta M; Muñoz E; Aliaga R; Vera A; Alfaro-Cervelló C; Jordá E; Garcés-Albir M; Roda D; Dorcaratto D; Tarazona N; Torondel S; Guijarro J; Sánchiz V; Gambardella V; Fleitas-Kanonnikoff T; Lluch P; Pascual I; Ferrández A; Sabater L; Cervantes A
    ESMO Open; 2020 Nov; 5(6):e000929. PubMed ID: 33229503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved outcomes for borderline resectable adenocarcinoma of the pancreas after neoadjuvant chemotherapy in a community cancer center.
    Curto EM; Kaza AG; Sturdevant DA; Tuvin DM; Ganai S; Sticca RP
    Am J Surg; 2022 Dec; 224(6):1426-1431. PubMed ID: 36372580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer.
    Nakajima H; Yamaguchi J; Takami H; Hayashi M; Kodera Y; Nishida Y; Watanabe N; Onoe S; Mizuno T; Yokoyama Y; Ebata T
    Int J Clin Oncol; 2023 May; 28(5):688-697. PubMed ID: 36872415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials.
    Aliseda D; Martí-Cruchaga P; Zozaya G; Blanco N; Ponz M; Chopitea A; Rodríguez J; Castañón E; Pardo F; Rotellar F
    BJS Open; 2024 Sep; 8(5):. PubMed ID: 39329454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer].
    Lee SH
    Korean J Gastroenterol; 2024 Sep; 84(3):103-110. PubMed ID: 39319431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.